Preventing pressure ulcers with gentle application of Rivadouce vegetable skincare oil
Official title: Prevention of Pressure Ulcers by Effleurage With RIVADOUCE VEGETABLE SKINCARE OIL in Patients at Risk of Pressure Ulcers: Observational Study
Run by Laboratoires RIVADIS · NCT07045480 · Data updated 2026-11-12
This project will test whether gently massaging Rivadouce vegetable skincare oil onto pressure-prone skin helps prevent pressure ulcers in adults at risk.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 252 (estimated) |
| Sponsor | Laboratoires RIVADIS Industry-sponsored |
| Locations | 1 site (Multiple Locations) |
| Status | Recruiting |
| Started | April 4, 2025 |
| Main results expected | January 31, 2026 |
| Study ends | January 31, 2026 |
| Registry record updated | July 1, 2025 |
| Trial ID | NCT07045480 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults at risk for pressure ulcers (Braden score <18), without existing pressure ulcers, who will receive the oil as part of their facility's prevention protocol and will remain in the facility for about 35 days are ideal candidates.
✕Probably not a fit
Patients who already have pressure ulcers, are at end of life, plan to use multilayer dressings on target areas, or are not covered by social health insurance are unlikely to be eligible or to benefit from this follow-up.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, non-interventional multicenter post-market follow-up conducted in real-life conditions across French care facilities. Adults at risk (Braden score <18) with no existing pressure ulcers will receive the product applied by effleurage to pressure-prone sites as part of routine prevention measures and be followed for 35 ± 5 days. The primary outcome is the proportion of patients developing at least one stage 1 or higher pressure ulcer on treated areas using NPUAP classification. The study enrolls about 252 patients across 10–20 centers to collect clinical performance and safety data for the marketed product.
Why it matters
Potential benefit: If successful, the product could reduce new pressure ulcers by offering a simple topical preventive option that integrates into routine care.
How similar studies have gone: Similar approaches using topical emollients and gentle massage have produced mixed but sometimes favorable findings in smaller or non-randomized studies, so this post-market follow-up aims to add real-world data for this specific product.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years at the time of inclusion. * At risk of developing pressure ulcers, as determined by clinical judgment and a Braden Scale score \<18. * No existing pressure ulcer at the time of inclusion. * Informed consent signed by the patient, or by a trusted third party or legal representative (for protected adults), after being informed about the study. * Expected length of stay ≥ 35 days ±5 days in the participating facility. * Planned use of RIVADOUCE VEGETABLE SKINCARE OIL on one or more pressure-prone areas as part of the facility's standard pressure ulcer prevention protocol. Exclusion Criteria: * Use or planned use of multilayer dressings on the pressure-prone areas to be treated with the study product. * End-of-life patients, defined as having an estimated life expectancy of less than 3 months. * Patients who are not covered by social health insurance.
Where it's running
-
Multiples facilities
Multiple Locations, France Recruiting
Study contacts
- Principal investigator: Sylvie MEAUME, PhD — Hôpital Rotschild
- Study coordinator: Renaud Urbinelli
- Email: etudes@clin-experts.fr
- Phone: +33658687286
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comparing two types of dressings for preventing pressure ulcers in cardiac surgery patients
This study is testing which type of dressing, either polyurethane foam or Mepilex, works better to prevent pressure ulcers in patients having heart surgery.
-
THERAVEX Tissue Care Spray Plus for Healing of Skin Wounds and Ulcers
This observational review tests whether THERAVEX Tissue Care Spray Plus, used with standard wound care, helps heal various skin wounds and chronic ulcers in adults.
-
Single-layer amniotic membrane (XPURT) plus standard care for chronic pressure ulcers
This project will try adding a single-layer amniotic membrane (XPURT) to standard wound care to see if it helps close nonhealing stage 3–4 pressure ulcers in adults.
-
Cellular, acellular, and matrix wound products plus standard care for nonhealing stage 3–4 pressure ulcers
This study will try several cellular, acellular, and matrix-like wound products with standard care to see if adults with nonhealing stage 3–4 pressure ulcers heal more completely over 20 weeks than with standard care alone.
-
Surgical and antibiotic treatment for pressure ulcers linked to osteomyelitis
This study is testing if a combined surgery and antibiotic treatment can help people with neuromotor disabilities who have pressure ulcers linked to bone infections heal better.
-
Using different masks to prevent pressure sores in patients with respiratory failure
This study tests if using different types of masks during breathing support can help prevent pressure sores in patients with severe breathing problems.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.